SecBot SecBot
SECBOTREPLAY Home › Report › VTRS

VTRS · The district court partially granted Teva's motion to dismiss Mylan's…

Viatris Inc · COURT-RULING filed Apr 12, 2026 at 20:00 ET

At the news

BEARISHIMPACT 5/10

COURT-RULING filed Apr 12, 2026 at 20:00 ET

The district court partially granted Teva's motion to dismiss Mylan's antitrust complaint, dismissing with prejudice allegations regarding sham citizen petitions, ANDA lawsuits, market shift, copay assistance, and foreign conduct, but allowing claims based on the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition to proceed. The ruling significantly narrows Viatris's (Mylan's) antitrust case against Teva, reducing the potential scope of damages.

  • Court adopted Special Master's R&R, partially granting Teva's motion to dismiss.
  • Antitrust allegations regarding 20mg citizen petitions, 20mg ANDA litigation, market shift, copay assistance, and foreign conduct dismissed with prejudice.
  • Allegations about DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit survive.
  • Lanham Act claim (Count II) and state law claims (Counts III-VI) survive.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access